Price
No data yet.
Social Signal Score
Analyst Ratings
12 analystsRevenue
$678.20M-12.94%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Anshul Thakral
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 14,000
- Beta
- 1.91
- Country
- US
- Piotroski score
- 5 / 9 (Middling)
- Altman Z-score
- 0.80
Financials
Revenue
$678.20M-12.9%Net Income
$-13.20M-140.6%EBITDA
$34.40M-43.7%Free Cash Flow
$-25.50MEPS (diluted)
$-0.14-137.8%Shares Outstanding (diluted)
94.29M+6.4%Operating Expenses
$102.10MCash & Debt
$168.60MRevenue by Segment (annual)
$2.72BQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $2.72B | $-986.20M | $-10.81 |
| 2024 | $2.70B | $-328.50M | $-3.67 |
| 2023 | $2.84B | $-25.20M | $-0.04 |
| 2022 | $2.84B | $186.20M | $2.11 |
| 2021 | $3.06B | $98.00M | $1.11 |
| 2020 | $2.58B | $-359.20M | $-4.06 |
Valuation
FTREhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
50+0.00%Social Signal Score
Mentions (5)
- Newsglobenewswire.com·9d ago·Neutral
Fortrea Announces Date for Third Quarter 2026 Financial Results and Conference Call DURHAM, N.C., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE) (the “Company”), a leading global contract research organization (“CRO”), today announced that it will release its third quarter 2026 financial results before the market opens on Thursday, October 29, 2026. The Company will host a conference call at 8:00 a.m. ET on that day to discuss the results.
View source ↗ - Newsglobenewswire.com·34d ago·Negative
Fortrea Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) DURHAM, N.C., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE) (the “Company”), a leading global contract research organization (“CRO”), today announced the granting of an inducement award of restricted stock units (“RSUs”) and performance share units (“PSUs”) on September 10, 2026, to five newly hired employees.
View source ↗ - Newsbenzinga.com·42d ago·Neutral
Fortrea Leverages Early Phase Strengths to Accelerate Market Expansion Fortrea (NASDAQ:FTRE) signed a definitive agreement to acquire the Early Phase Services division of Worldwide Clinical Trials in an all-cash transaction valued at approximately $45 million.
View source ↗ - Newsglobenewswire.com·42d ago·Neutral
Fortrea to Acquire Clinical Pharmacology Unit and Bioanalytical Laboratory Operations from Worldwide Clinical Trials Adds dedicated bioanalytical capabilities and expanded capacity to Fortrea's early clinical development network as Worldwide advances its strategy to scale clinical development, therapeutic leadership and high-growth markets Adds dedicated bioanalytical capabilities and expanded capacity to Fortrea's early clinical development network as Worldwide advances its strategy to scale cl
View source ↗ - Newsseekingalpha.com·45d ago·Neutral
Fortrea Holdings: The Turnaround Is Showing Up In Earnings Before Revenue Fortrea Holdings Inc. is rated Buy at ~$18.86, driven by an earnings turnaround from aggressive cost reductions, not revenue growth. Adjusted EBITDA rose ~24% in H1 despite a ~3.4% revenue decline, as direct costs and SG&A fell faster than sales. Net new business awards increased ~19% YoY, with a trailing-12-month book-to-bill ratio of 1.12x, but revenue conversion remains uncertain.
View source ↗
Earnings
Thu, Oct 29(in 2 weeks)
Consensus estimate $0.22 per share
Typical surprise +27.5% (median, so one quarter with a near-zero estimate can't distort it)
- Wed, Jul 29$0.23 vs $0.18beat
- Tue, May 5$0.16 vs $0.03beat
- Thu, Feb 26$0.09 vs $0.16miss
- Wed, Nov 5$0.12 vs $0.16miss
- Wed, Aug 6$0.19 vs $0.06beat
- Mon, May 12$0.02 vs $-0.07beat
Estimates and results for FTRE via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by FTRE officers and directors.
- Bought
- $100k
- Sold
- $4.7m
1 trade
28 trades
- Russell Carrie Elizabethsold
- Morais Mark A.sold
- Morais Mark A.sold
- Thakral Anshulsold
- Thakral Anshulsold
- Thakral Anshulsold
- Thakral Anshulsold
- Sanders Machellesold
71 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
- French Hillhouse · AR02 · disclosed Jul 25, 2025 (32d later)Sell$1,001 - $15,000
Self-reported filings, amounts as brackets. Via Senate/House disclosures.